Sarkoidosis

01Pathophysiology

Sarcoidosis is a systemic inflammatory disease driven by an exaggerated CD4+ T-helper type 1 (Th1) immune response. The current understanding is that an unidentified antigen, possibly environmental, microbial, or self-derived, triggers a disproportionate immune reaction in genetically predisposed individuals. The activated CD4+ T cells release interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), which recruit and activate macrophages at the site of inflammation.

These activated macrophages transform into epithelioid cells and fuse to form multinucleated giant cells. The end result is the formation of well-organized, tightly packed collections of immune cells known as noncaseating granulomas. The term "noncaseating" is critical because it distinguishes sarcoidosis from tuberculosis and fungal infections, which produce caseating (centrally necrotic) granulomas. On biopsy, these granulomas may contain Schaumann bodies (laminated calcium and protein inclusions) and asteroid bodies (star-shaped inclusions within giant cells), both of which are suggestive but not pathognomonic.

A frequently tested consequence of granuloma formation is hypercalcemia. The macrophages within the granulomas express 1-alpha-hydroxylase, an enzyme that converts 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol). This ectopic, unregulated production of calcitriol increases intestinal calcium absorption, leading to hypercalcemia and hypercalciuria. This is the same enzyme found in the kidney, but in sarcoidosis, its activity is independent of PTH regulation. The resulting hypercalcemia can cause nephrolithiasis, nephrocalcinosis, and if severe, renal failure.

The epithelioid cells and macrophages within the granulomas also produce angiotensin-converting enzyme (ACE). While elevated serum ACE is a classic laboratory finding in sarcoidosis, it is neither sensitive nor confirmatory on its own. It is better used for monitoring disease activity over time rather than for initial diagnosis.

Because sarcoidosis is a systemic disease, granulomas can deposit in virtually any organ, which explains the wide variety of presentations. The lungs and hilar lymph nodes are most commonly involved (over 90% of cases), but the skin, eyes, liver, spleen, heart, nervous system, and musculoskeletal system can all be affected. The reason the disease often resolves spontaneously, particularly in early stages, is that the granulomatous inflammation can self-limit once the immune stimulus diminishes. However, in some patients, chronic inflammation leads to irreversible fibrosis.

02Classification and Clinical Manifestation

Scadding Radiographic Staging (Chest X-Ray)

This classification is one of the most testable aspects of sarcoidosis. It predicts prognosis and likelihood of spontaneous resolution.

The key teaching point is that the higher the stage, the lower the chance of spontaneous remission. Stage I has an excellent prognosis and most patients never need treatment. Stage IV represents end-stage fibrotic disease.

Named Clinical Syndromes

Organ-by-Organ Manifestations

03Diagnostic Workup

The diagnostic process for sarcoidosis begins with the clinical presentation and imaging. When a young patient, particularly an African American woman in her 20s to 30s, presents with cough, dyspnea, and a chest X-ray showing bilateral hilar lymphadenopathy, sarcoidosis should be at the top of the differential. The chest X-ray is the best initial test because it is readily available and demonstrates the hallmark finding in most patients.

However, bilateral hilar lymphadenopathy is not exclusive to sarcoidosis. Lymphoma and infections can produce a similar appearance. For this reason, the diagnosis requires histologic confirmation. A tissue biopsy demonstrating noncaseating granulomas is the gold standard. The most commonly biopsied sites include the lung (via transbronchial biopsy during bronchoscopy), skin lesions, and peripheral lymph nodes. It is essential that the biopsy specimen is also sent for AFB stain, fungal stain, and culture to exclude tuberculosis and fungal infections, because those conditions produce granulomas as well but with caseation and identifiable organisms.

Serum ACE is frequently ordered but should not be used to confirm or exclude the diagnosis. It has poor sensitivity (around 60%) and poor specificity (elevated in other granulomatous diseases). Its primary utility is in tracking disease activity in patients with established sarcoidosis. A rising ACE level may suggest disease flare, while a falling level may indicate treatment response.

Serum calcium and 24-hour urine calcium should be checked in all patients because hypercalcemia and hypercalciuria are treatable complications. If hypercalcemia is found, a 1,25-dihydroxyvitamin D level will be elevated, confirming the ectopic calcitriol production by granulomas. Note that the PTH level will be suppressed (not elevated), which distinguishes this from primary hyperparathyroidism.

Pulmonary function tests typically show a restrictive pattern with reduced FVC and TLC, along with a decreased DLCO reflecting impaired gas exchange due to granulomatous inflammation of the interstitium. In some cases, particularly with endobronchial disease, an obstructive pattern may coexist.

Bronchoalveolar lavage showing a CD4-to-CD8 ratio greater than 3.5:1 is supportive of the diagnosis, though not confirmatory on its own. This reflects the Th1 lymphocyte predominance in the alveolar space.

All patients with sarcoidosis should undergo an ECG at baseline to screen for cardiac involvement, which can present insidiously with heart block or arrhythmias. Cardiac MRI with late gadolinium enhancement is used when cardiac sarcoidosis is suspected and can reveal myocardial granulomatous infiltration.

04Management and Treatment

The cornerstone principle for exam purposes is that not all patients with sarcoidosis require treatment. Many cases, particularly Stage I, resolve spontaneously within 12 to 24 months. Treatment is indicated when there is significant organ dysfunction, progressive symptoms, or dangerous extrapulmonary involvement (cardiac, neurologic, ocular disease unresponsive to topical therapy, or symptomatic hypercalcemia).

When treatment is indicated, systemic corticosteroids are first-line. The typical regimen is prednisone 20 to 40 mg daily for an initial period of 4 to 6 weeks. If the patient responds, the dose is gradually tapered over 6 to 12 months. Abrupt discontinuation should be avoided because relapse rates are high. Some guidelines suggest a total treatment duration of at least 12 months for pulmonary sarcoidosis.

For patients who cannot tolerate long-term corticosteroids due to side effects (weight gain, diabetes, osteoporosis, adrenal suppression) or who relapse upon tapering, steroid-sparing agents are introduced. Methotrexate is the most commonly used second-line agent, typically dosed at 10 to 15 mg per week with concurrent folic acid supplementation. Azathioprine and mycophenolate mofetil are alternatives.

Hydroxychloroquine has a role primarily in skin-predominant sarcoidosis and hypercalcemia, though it is less potent than corticosteroids for pulmonary disease.

For truly refractory cases, infliximab (an anti-TNF-alpha monoclonal antibody) has demonstrated efficacy. This is because TNF-alpha is a central cytokine in granuloma formation and maintenance, making it a logical therapeutic target.

Corticosteroids effectively treat hypercalcemia in sarcoidosis by directly inhibiting the 1-alpha-hydroxylase enzyme in granulomas, reducing calcitriol production. This is a highly testable point, as it differs from the management of hypercalcemia in malignancy or hyperparathyroidism.

Cardiac sarcoidosis and neurosarcoidosis warrant aggressive immunosuppression from the outset, and device therapy (pacemaker, implantable cardioverter-defibrillator) should be considered when conduction abnormalities or life-threatening arrhythmias are present.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students answer sarcoidosis questions incorrectly is by confusing noncaseating granulomas with caseating granulomas. When a vignette describes a young patient with bilateral hilar lymphadenopathy and a biopsy showing noncaseating granulomas, the answer is sarcoidosis. The moment "caseating" or "central necrosis" appears, the diagnosis shifts to tuberculosis or a fungal infection. This distinction must be automatic.

A second trap involves the mechanism of hypercalcemia. Students often select primary hyperparathyroidism as the cause of elevated calcium in a sarcoidosis patient. The differentiator is straightforward: in sarcoidosis, PTH is suppressed (because the hypercalcemia is driven by excess 1,25-dihydroxyvitamin D from granulomas, not by parathyroid hormone). If the question provides both a calcium level and a PTH level, check the PTH first.

A third common error is initiating corticosteroid therapy for every patient diagnosed with sarcoidosis. Exam questions frequently test the concept that Stage I sarcoidosis with bilateral hilar lymphadenopathy alone, in an asymptomatic patient, requires observation only. Treatment is reserved for patients with progressive or organ-threatening disease.

Students also miss the connection between sarcoidosis and erythema nodosum. When a vignette describes a young woman with bilateral ankle pain, tender red nodules on the shins, and bilateral hilar lymphadenopathy, this is Lofgren syndrome. This specific combination carries an excellent prognosis and is a classic "pattern recognition" question.

Finally, be alert for the cardiac and neurologic complications. If a patient with known sarcoidosis develops a new heart block (especially third-degree AV block in a young person), the question is testing your recognition of cardiac sarcoidosis. Similarly, unilateral or bilateral facial nerve palsy in the setting of hilar lymphadenopathy should trigger consideration of neurosarcoidosis (or the complete Heerfordt syndrome if parotid swelling and uveitis are also present).

The core competency being tested across all sarcoidosis questions is pattern recognition of the classic demographic, imaging findings, and histopathologic features, combined with the ability to distinguish it from infectious granulomatous diseases and to apply the correct management threshold.